Correlative study on the expression of p53 and DNA ploidy in acute nonlymphocytic leukemia

Abstract

We used the flow cytometric immunoassay to study the correlation between the tumor-suppressor gene product p53⁻ and the DNA ploidy in 30de novo cases of acute nonlymphocytic leukemia (ANLL). The results showed that 15 cases were negative and the other 15 cases were positive expression for p53. As compared with p53 negative (p53) cases, the patients with positive p53 (p53⁺) had higher percentage of bone marrow blasts and lower peripheral leukocyte and platelet counts, which had no influence on the complete remission rate. Before treatment, DNA diploidy was seen in 18 cases including 12 p53⁻ cases, and DNA aneuploidy in 12 cases including 9 p53⁺. After therapy, aneuploidy could be transformed into diploidy. Patients with P53⁺ or having aneuploidy in complete remission were at risk for early relapse. We believe that p53 may be involved in the process of leukemogenesis and progression of ANLL.

Keywords

p53 tumor-suppressor gene / DNA ploidy / flow cytometry / acute nonlymphocytic leukemia

References

[1] LevineA J, MomandJ, FinlayC A. The p53 tumor suppressor gene. Nature, 1991, 351: 453-453

[2] HarrisC C, HollsteinM. Clinical implication of the p53 tumor-suppressor gene. N Eng J Med, 1993, 329: 1318-1318

[3] ZhangR X, YaoE G. The prognostic significance of flow cytometry DNA measurement in acute leukemia. Chin J Hematol, 1989, 10: 415-415

[4] ZhangR X, YaoE G. Flow cytometry DNA measurement for prediction of effect of therapy in acute leukemia. J Tongji Med Uni, 1990, 10: 181-181

[5] ZhangR X, YaoE G. Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia. Chin Med J, 1990, 103: 826-826

[6] DanovaM, GiordanoM, MazziniG, et al.. Expression of p53 protein during the cell cycles measured by flow cytometry in human leukemia. Leu Res, 1990, 14: 417-417

[7] QiF Y, QingT W, LiuX Y, et al.. Study on the expression of ras oncogene product p21 and DNA ploidy in oral squamous cell carcinoma. Chin J Phy Med, 1993, 15: 24-24

[8] SmithL J, McCullochA M, BenchimolS. Expression of the p53 oncogene in acute myeloblastic leukemia. J Exp Med, 1986, 164: 751-751

[9] LangoisR G, BigbeeW L, JensenR H. Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus. Hum Genet, 1986, 74: 353-353

[10] BigheeW L, WyrobekA J, LangoisR G, et al.. The effect of chemotherapy on the in vivo frequency of glycophorin A “ null” variant erythrocytes. Mut Res, 1990, 240: 165-165